| CTRI Number |
CTRI/2026/04/107563 [Registered on: 06/04/2026] Trial Registered Prospectively |
| Last Modified On: |
23/03/2026 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug Surgical/Anesthesia |
| Study Design |
Randomized, Parallel Group Trial |
|
Public Title of Study
|
ICG Fluorescence-Guided vs Conventional approach on surgical outcomes in Pancreatic Head Resection for Chronic Pancreatitis
|
|
Scientific Title of Study
|
Effect Of Indocyanine Green Fluorescence Guided Real Time Surgery Vs Conventional Approach on Surgical Outcomes in Patients Undergoing Bile Duct and Duodenum Preserving Pancreatic Head Resection Surgery for Chronic Pancreatitis- A Randomized Controlled Trial |
| Trial Acronym |
nil |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| nil |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Greeshma Unnikrishnan |
| Designation |
Junior Resident |
| Affiliation |
Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry |
| Address |
Junior Resident
Department of Surgery
Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry
JIPMER Campus Rd, Gorimedu
Dhanvantari Nagar
Puducherry
Pondicherry PONDICHERRY 605006 India |
| Phone |
8296658292 |
| Fax |
|
| Email |
greeshma.ushus@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Shanmugam D |
| Designation |
Professor |
| Affiliation |
Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry |
| Address |
Professor
Department of Surgery
Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry
JIPMER Campus Rd, Gorimedu
Dhanvantari Nagar
Puducherry
Pondicherry PONDICHERRY 605006 India |
| Phone |
9787273017 |
| Fax |
|
| Email |
shandsge@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
Dr Shanmugam D |
| Designation |
Professor |
| Affiliation |
Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry |
| Address |
Professor
Department of Surgery
Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry
JIPMER Campus Rd, Gorimedu
Dhanvantari Nagar
Puducherry
Pondicherry PONDICHERRY 605006 India |
| Phone |
9787273017 |
| Fax |
|
| Email |
shandsge@gmail.com |
|
|
Source of Monetary or Material Support
|
| Jawaharlal Institute of Postgraduate Medical Education and Research, JIPMER Campus Rd, Gorimedu, Dhanvantari Nagar, Puducherry - 605006, India
04132296562 |
|
|
Primary Sponsor
|
| Name |
Dr. Greeshma Unnikrishnan |
| Address |
Junior Resident
Department of Surgery
Jawaharlal Institute of Postgraduate Medical Education and Research
JIPMER Campus Rd Gorimedu
Dhanvantari Nagar
Puducherry 605006 |
| Type of Sponsor |
Other [Self] |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Greeshma Unnikrishnan |
Jawaharlal Institute of Postgraduate Medical Education and Research |
Department of Surgery and Surgical Gastroenterology Pondicherry PONDICHERRY |
8296658292
greeshma.ushus@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| INSTITUTIONAL ETHICS COMMITTEE-INTERVENTIONAL STUDIES JIPMER, PUDUCHERRY |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: K861||Other chronic pancreatitis, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Patients undergo Bile duct and Duodenum preserving pancreatic head resection with intraoperative indocyanine green (ICG) fluorescence for real-time cholangiography to identify the bile duct and intravenous angiography to visualize vascular arcades and to assess duodenal perfusion. |
Under strict aseptic precautions, one vial of indocyanine green (ICG) containing 25 mg of lyophilized dye will be reconstituted with 10 mL of sterile water for injection, thereby yielding a concentration of 2.5 mg/mL. The reconstituted vial will be used within six hours to maintain stability of the dye. A test dose of 0.1 mL will be administered intravenously under anaesthetic monitoring to detect any allergic or adverse reaction. For biliary mapping, single dose administration of ICG will be done intravenously at a dose of 2.5 mg approximately 60 minutes before skin incision.The surgical technique of DPPHR will be performed according to standard steps: Kocherization of the duodenum, exposure of the pancreatic head, coring of inflammatory pancreatic tissue, careful preservation of the bile duct, hemostasis, and reconstruction of the pancreatic remnant. For arterial and duodenal arcade perfusion assessment, 5 mg IV will be injected during mobilization or after pancreatic head coring, followed by a 10 mL saline flush. Near-infrared (NIR) light will be used to record perfusion parameters. Fluorescence will be visualized with an open-surgery compatible near-infrared (NIR) system. The duration of the intervention would be approximately 15 minutes for the injection of the dye, and observation of bile duct and vascular arcades. |
| Comparator Agent |
Patients undergo standard DPPHR without ICG; bile duct and perfusion are assessed by conventional anatomical dissection and visual cues alone. |
The surgical technique of DPPHR will be performed according to standard steps: Kocherization of the duodenum, exposure of the pancreatic head, coring of inflammatory pancreatic tissue, careful preservation of the bile duct, hemostasis, and reconstruction of the pancreatic remnant. Bile duct and perfusion are assessed by conventional anatomical dissection and visual cues alone. |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
90.00 Year(s) |
| Gender |
Both |
| Details |
Adult patients with chronic pancreatiitis requiring surgical management |
|
| ExclusionCriteria |
| Details |
1. Patients with Chronic Pancreatitis with suspicion of malignancy
2. Previous pancreatic surgeries
3. Portal hypertension with varices or major vascular thrombosis.
4. Severe hepatic or renal impairment eGFR less than 30 mL/min/1.73m²).
5. Patients with Chronic Pancreatitis with distal biliary stricture
6. Patients with Chronic Pancreatitis who many require additional surgical procedures (Cystojejunostomy, Distal pancreatectomy, Splenectomy)
7. Known allergy to ICG or iodides.
8. Pregnancy or lactation.
|
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
|
Method of Concealment
|
Sequentially numbered, sealed, opaque envelopes |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
| To determine whether using indocyanine green (ICG) fluorescence during surgery lowers the risk of bile duct-related complications in patients undergoing bile duct and duodenum-preserving pancreatic head resection (DPPHR), such as intraoperative injury, postoperative bile leak, or stricture within 90 days |
To determine whether using indocyanine green (ICG) fluorescence during surgery lowers the risk of bile duct-related complications in patients undergoing bile duct and duodenum-preserving pancreatic head resection (DPPHR), such as intraoperative injury, postoperative bile leak, or stricture within 90 days |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
To compare overall morbidity within 30 days classified by Clavien–Dindo grade, length of hospital stay (days) & readmission within 30 days between the ICG & non ICG groups.
To compare functional endocrine & exocrine outcomes at 90 days between the ICG & non ICG groups.
To compare the adequacy of head coring at 3 months (defined as absence of more than 5 mm residual pancreatic head tissue) radiologically using CT, postoperative pain reduction using COMPAT-SF score, & quality of life using EORTC C30 global health score between the ICG & non ICG groups.
To assess the proportion of patients with preserved duodenal perfusion confirmed by ICG angiography (uniform fluorescence of duodenum within 60 seconds of injection).
To assess ICG-related adverse events (anaphylaxis, urticaria, hypotension, or injection-site reactions) documented perioperatively.
|
Overall morbidity will be assessed within 30 days
Functional endocrine & exocrine outcomes will be assessed at 90 days.
Adequacy of head coring will be assessed at 90 days.
Post opertaive pain reduction & quality of life will be assessed ay 90 days.
Proportion of patients with preserved duodenal perfusion will be assessed as uniform fluorescence of duodenum within 60 seconds of injection
ICG related adverse events will be documented perioperatively
|
|
|
Target Sample Size
|
Total Sample Size="36" Sample Size from India="36"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
Phase 3 |
|
Date of First Enrollment (India)
|
06/04/2026 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="3" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Yet Recruiting |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Bile Duct and Duodenum-preserving pancreatic head resection (DPPHR) is a function-preserving surgical alternative to pancreatoduodenectomy for patients with chronic pancreatitis. By preserving the duodenum and distal bile duct, DPPHR provides effective long-term pain relief while maintaining pancreatic endocrine and exocrine function and improving nutritional outcomes. Several meta-analyses and long-term studies have demonstrated that DPPHR leads to superior functional outcomes compared to pancreatoduodenectomy, including lower rates of new-onset diabetes and exocrine insufficiency. However, achieving adequate pancreatic head coring is crucial for effective pain control, while excessive resection may compromise the common bile duct (CBD) or surrounding vascular structures. Protecting the CBD and maintaining duodenal vascularity remain significant intraoperative challenges, particularly in patients with distorted anatomy due to chronic inflammatory fibrosis. Conventional techniques depend largely on the surgeon’s experience and visual assessment, which may not consistently ensure ductal safety or adequate perfusion.
Indocyanine green (ICG) fluorescence imaging is a technique that enables real-time intraoperative cholangiography and perfusion assessment. Early studies suggest that ICG-guided DPPHR may improve visualization of the bile duct, confirm adequate duodenal vascularity, and help assess the completeness of pancreatic head resection. However, existing evidence is limited, as most studies are retrospective with small sample sizes and focus mainly on technical feasibility. There is a lack of randomized controlled trials (RCTs) evaluating the effectiveness of ICG guidance in DPPHR.
To address this gap, the present study is designed as a prospective RCT comparing DPPHR performed with ICG guidance to conventional DPPHR without fluorescence imaging. The study will be conducted in the Department of Surgery and Surgical Gastroenterology at JIPMER. Patients with chronic pancreatitis planned for open bile duct and duodenum-preserving pancreatic head resection will be screened for eligibility and enrolled after informed consent. Preoperative evaluation will include demographic details, clinical examination, laboratory investigations, and imaging to assess pancreatic, biliary, and vascular anatomy.
Participants will be divided into two groups. The intervention group will undergo ICG-guided DPPHR, where intraoperative fluorescence imaging will be used for real-time identification of the bile duct and evaluation of duodenal and arterial arcade perfusion. The control group will undergo conventional DPPHR based on standard anatomical dissection and visual assessment. ICG will be administered intravenously following standardized hepatopancreatobiliary surgery protocols. A dose of 2.5 mg will be given approximately 60 minutes before incision for biliary mapping, while an additional 5 mg will be administered intraoperatively to assess arterial and duodenal perfusion using near-infrared imaging. Perfusion parameters such as time to fluorescence (Tmax) and half-rise time (T½MAX) will be recorded to evaluate vascular adequacy.
Fluorescence imaging will be performed at three standardized intraoperative stages: before pancreatic head coring for biliary mapping, after coring to assess arterial arcade perfusion, and before closure to detect bile leaks or compromised vascularity. Intraoperative data collected will include operative time, blood loss, transfusion requirements, complications, and ICG dosing. Postoperative monitoring will follow enhanced recovery after surgery (ERAS) protocols, with assessment of complications such as cholangitis, obstructive jaundice, bile leak, bile duct stricture, pancreatic fistula, intra-abdominal collections, and delayed gastric emptying according to established international criteria.
The primary outcome of the study will be the incidence of bile duct injury or postoperative bile leak within 90 days. Secondary outcomes will include accuracy of biliary identification, adequacy of duodenal perfusion, operative parameters, postoperative morbidity, hospital stay, and reintervention rates. Fluorescence recordings will be independently evaluated by to assess signal strength, completeness, and homogeneity. |